Status
Conditions
About
The goal of this clinical trial is to learn about the mutation spectrum of homologous recombination repair pathway genes and its instructive significance in the treatment of Chinese breast cancer patients.
Full description
The main questions it aims to answer are:
Enrollment
Sex
Volunteers
Inclusion criteria
Pathology-confirmed breast cancer patients who meet at least one of the criteria below:
A: Neoadjuvant phase: non-pathological complete response for triple-negative breast cancer; non-pathological complete response AND CPS+EG score ≥ 3 for hormone receptor positive breast cancer B: Adjuvant phase: ≥ pT2 or ≥ pN1 for triple-negative breast cancer; ≥ 4 lymph node metastasis for hormone receptor positive breast cancer
Having been or intended to be tested for germline and (or) somatic homologous recombination repair gene mutations
Consent to providing medical charts and homologous recombination repair gene testing results, and being cooperative for long-term follow-up
Exclusion criteria
Loading...
Central trial contact
Yiwei Tong; Xiaosong Chen
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal